Adenocarcinoma Of Esophagus clinical trials

Every program with a company-led study here in the last two years, whatever its size: 16 programs from 14 companies, 3 with this as their studies’ main aim; 5 with a live phase 3 study; 2 primary completions in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

16 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 16 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

• 30 Nov 2026 est.KRAS G12D Degrader ARV-806 · Arvinas Inc. · Phase 2 registry mapping onlyNCT07023731 A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation — primary endpoint: Part A (Phase 1): Number of dose-limiting toxicities (DLTs) of ARV-806 · 76 enrolled
• 14 Mar 2027 est.ebnk-1822h2 dual-target cldn18.2 · Beijing Biotech · Phase 2 registry mapping onlystudied with fludarabinestudied with CyclophosphamideNCT07622940 Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 36 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.